Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U A Matulonis

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 17, 2018
Safety and dose modification for patients receiving niraparibJ S Berek, U A Matulonis, U Peen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 3, 2019
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 studyU A Matulonis, R Shapira-Frommer, A D Santin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 30, 2016
Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancerJ F Liu, K N Moore, M J Birrer, et al.
Gynecologic Oncology|September 28, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trialMansoor R Mirza, B Benigno, A Dørum, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancerU A Matulonis, G M Wulf, W T Barry, et al.
Pageof 3